PTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at Truist Financial
Equities researchers at Truist Financial started coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $80.00 price target on the biopharmaceutical company’s stock. Truist Financial’s target price points to a potential upside […]
Equities researchers at Truist Financial started coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $80.00 price target on the biopharmaceutical company’s stock. Truist Financial’s target price points to a potential upside […]
